Protein Modulation Drugs Nurix Therapeutics is developing targeted protein modulation drugs to treat patients with cancer and inflammatory diseases, presenting a sales opportunity to healthcare facilities and oncology centers.
Key Personnel Expansion The recent appointment of John Northcott as the chief commercial officer signifies Nurix's strategic focus on expansion, indicating potential partnerships and B2B sales avenues.
Pivotal Clinical Program Launch With the upcoming launch of the pivotal clinical program for NX-5948 focusing on chronic lymphocytic leukemia, Nurix Therapeutics offers a sales opportunity for medical research centers and pharmaceutical distributors.
Corporate Event Participation Nurix's active participation in industry conferences like the Oppenheimer Healthcare Life Sciences Conference opens avenues for networking and potential sales collaborations in the biotechnology sector.
Financial Stability and Growth With solid revenue between $50M to $100M and funding of $175M, Nurix presents a stable partnership opportunity for investors, fostering confidence for potential sales agreements and long-term business relationships.
$10M
$50M$100M
$50M$100M
$10M$50M
$10M$50M
$10M$50MNurix Therapeutics uses 8 technology products and services including GoTo Meeting, jQuery CDN, Google Cloud, and more. Explore Nurix Therapeutics's tech stack below.
| Nurix Therapeutics Email Formats | Percentage |
| FLast@nurixtx.com | 71% |
| Last@nurixtx.com | 26% |
| First.Last@nurixtx.com | 3% |
| FLast@nurix-inc.com | 88% |
| Last@nurix-inc.com | 8% |
| First@nurix-inc.com | 1% |
| FMiddleLast@nurix-inc.com | 1% |
| F.Last@nurix-inc.com | 1% |
| LastF@nurix-inc.com | 1% |
Biotechnology ResearchCalifornia, United States201-500 Employees
Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
Company Overview
Funding & FinancialsNurix Therapeutics has raised a total of $175M of funding over 8 rounds. Their latest funding round was raised on Apr 11, 2024 in the amount of $175M.
Nurix Therapeutics's revenue is in the range of $50M$100M
Funding & FinancialsNurix Therapeutics has raised a total of $175M of funding over 8 rounds. Their latest funding round was raised on Apr 11, 2024 in the amount of $175M.
Nurix Therapeutics's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com